Valemetostat tosylate clinical trials
Also written DS-3201b.
A product of Valemetostat; its studies count on that page too.
How each study uses valemetostat tosylate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the valemetostat tosylate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 4
Daiichi Sankyo (4) · Daiichi Sankyo Co., Ltd. (2) · The Lymphoma Academic Research Organisation (1) · Alliance for Clinical Trials in Oncology (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Carboplatin (1) · Cabazitaxel (1) · Abiraterone Acetate (1) · Abiraterone (1) · Enzalutamide (1) · Lutetium (¹⁷⁷Lu) vipivotide tetraxetan (1)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Valemetostat
Studies
Open first, then newest update. How each study uses valemetostat tosylate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Valemetostat TosylateHow we know
- Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.RecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07303387Written as Valemetostat TosylateHow we know
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruitingPhase 2Daiichi SankyoNCT04703192Written as Valemetostat TosylateHow we know
- A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive, not recruitingPhase 1/2Daiichi SankyoNCT06644768Written as valemetostat tosylateHow we know
- DS-3201b in Participants With LymphomasActive, not recruitingPhase 1Daiichi Sankyo Co., Ltd.NCT02732275Written as DS-3201bHow we know
- Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaActive, not recruitingPhase 2The Lymphoma Academic Research OrganisationNCT04842877Written as Valemetostat tosylateHow we know
- Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/LymphomaCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT04102150Written as Valemetostat TosylateHow we know
- DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung CancerTerminatedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03879798Written as DS-3201bHow we know
- DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)TerminatedPhase 1Daiichi SankyoNCT03110354Written as DS-3201bHow we know
- Study of Single-dose DS-3201b in Participants With Hepatic ImpairmentCompletedPhase 1Daiichi SankyoNCT04276662Written as DS-3201bHow we know
Given beside what is tested · 1 — valemetostat tosylate is usual care or a partner of the new treatment
Codes
What other systems call valemetostat tosylate · ClinicalTrials.gg INT015300
- UNII (FDA) 6N79I7X5IIVALEMETOSTAT TOSYLATEOne source FDA
- NCI Thesaurus C168589Valemetostat TosylateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6N79I7X5II | VALEMETOSTAT TOSYLATE | One source FDA |
| NCI Thesaurus | C168589 | Valemetostat Tosylate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.